he added capacity will further enhance WuXi Biologics’ commercial manufacturing capabilities in the U.S. The site is expected to employ 250 people...
Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium ...
As a result, Vetter has committed to the 1.5 degrees of global warming target. To this end, the CDMO has presented a sustainability strategy with concrete ...
Further develops its biosafety testing laboratories to meet local demand New labs complete 2nd phase of company’s € 29 million Biologics Test...
Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecule...
Three block copolymers added to RESOMER® portfolio of bioabsorbable polymers New nanoparticle process technology increases options for n...
Committed to sustainable growth and long-term planning Dedicated to making investments to support increased customer demand Maintain efficiency a...
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facilit...
Charles River Laboratories International, Inc. announced the launch of its lentiviral vector (LVV) manufacturing platform, Lentivation™. The pl...
New sites at Darmstadt and Hamburg complement Merck’s global integrated mRNA service network with pre-clinical to commercial capabilities Company&...
"Swiss CDMO Lonza Announces CEO Departure by Mutual Agreement; Chairman Baehny Takes the Helm Again Temporarily" Lonza, the Swiss Contract Development and...
Syneos Health is evolving its patient recruitment capabilities to further address unmet sponsor, site and patient needs. Through its collaboration with the...
Enzene Biosciences, a subsidiary of Mumbai-India, based Alkem Laboratories, has announced the inauguration of its cutting-edge research and...
ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to ...
© 2025 Biopharma Boardroom. All Rights Reserved.
